Off goes GBIO. The stock moved down today. Let's take a look:

 Shares of Generation Bio Co. (GBIO) are trading -9% lower at a price of $5.535 at the time of this writing. The stock is sinking faster than peers on a gloomy day for the Health Care sector.

There was no clear catalyst for the downwards move, other than a large macro swing in the market following the fed meeting today. Generation Bio last announced its earnings results on Thursday, August 4th and reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.03).

Generation Bio Co. has been trading between a 52-week high of $28.67 and a 52-week low of $3.96. The stock has a market cap of $327 Million.

Generation Bio is an innovative genetic medicines company focused on creating a new class of non-viral gene therapy to provide durable, redosable treatments for people living with rare and prevalent diseases. The company's non-viral platform incorporates a proprietary, high-capacity DNA construct called closed-ended DNA, or ceDNA; a cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The platform is designed to enable multi-year durability from a single dose of ceDNA and to allow titration and redosing if needed.